Idiopathic Pulmonary Fibrosis (IPF): An Overview.

J Clin Med · 2018 · PMC6111543 · PMID 30082599

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

An initial phase II study, the To Improve Pulmonary Fibrosis with BIBF 1120 (TOMORROW) study [ 126 ], suggested that nintedanib at a dose of 150 mg twice daily was effective at reducing FVC decline although failed to reach statistical significance.

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.